Back
Compare AU
Compare ISEC vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Enhanced Cash ETF (ISEC) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
ISEC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 73 |
Median incremental investment | $2,993.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $16,482.44 | $1,649.23 |
Average age group | > 35 | > 35 |
Key Summary
ISEC | CURE | |
|---|---|---|
Strategy | ISEC.AX was created on 2017-06-02 by iShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The ETF currently has 366.04m in AUM and 11 holdings. The Fund aims to provide investors with performance, before fees and expenses, in excess of the performance of an index comprised of Australian bank bills. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | RBC MONEY MARKET 11AM (13.55 %) UNITED OVERSEAS BANK LTD (SYDNEY B (5.02 %) NORFINA LTD (2.81 %) | Avidity Biosciences Inc Ordinary Shares (2.55 %) Revolution Medicines Inc Ordinary Shares (2.22 %) Exact Sciences Corp (2.16 %) |
Top 3 industries | Other (99.33 %) Communication Services (0.87 %) Consumer Discretionary (0.67 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.12 % | 0.45 % |
Key Summary
ISEC | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P/ASX Bank Bill Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.12 % | 0.45 % |
Price | $100.53 | $57.20 |
Size | $376.097 million | $36.803 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.03 % | 5.08 % |
Market | ASX | ASX |
First listed date | 06/06/2017 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
ISEC | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 6 | 73 |
Median incremental investment | $2,993.50 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $16,482.44 | $1,649.23 |
Average age group | > 35 | > 35 |
Pros and Cons
ISEC | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
ISEC | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |